Trials / Completed
CompletedNCT00818168
Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED)
Remicade Safety Line (Ankylosing Spondylitis)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 320 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study is in line with the German educational plan with the aim to implement a tool to increase and monitor the awareness of tuberculosis screening and to reinforce the patient eligibility for a treatment with Remicade according to the Summary of Product Characteristics (SmPc).
Detailed description
This study population was chosen from a non-probability sample.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Infliximab | Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC) |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2009-01-07
- Last updated
- 2015-09-03
- Results posted
- 2012-02-01
Source: ClinicalTrials.gov record NCT00818168. Inclusion in this directory is not an endorsement.